Praluent is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Sanofi-aventis U.s. Llc. The primary component is Alirocumab.
Product ID | 0024-5902_29fff6da-cf37-4a75-bdc5-abd63f28bc71 |
NDC | 0024-5902 |
Product Type | Human Prescription Drug |
Proprietary Name | Praluent |
Generic Name | Alirocumab |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2015-07-24 |
Marketing Category | BLA / BLA |
Application Number | BLA125559 |
Labeler Name | Sanofi-Aventis U.S. LLC |
Substance Name | ALIROCUMAB |
Active Ingredient Strength | 150 mg/mL |
Pharm Classes | PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2015-07-24 |
NDC Exclude Flag | N |
Sample Package? | Y |
Marketing Category | BLA |
Application Number | BLA125559 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-07-24 |
Marketing Category | BLA |
Application Number | BLA125559 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-07-24 |
Marketing Category | BLA |
Application Number | BLA125559 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-07-24 |
Ingredient | Strength |
---|---|
ALIROCUMAB | 150 mg/mL |
SPL SET ID: | 446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0024-5901 | Praluent | alirocumab |
0024-5902 | Praluent | alirocumab |
0024-5903 | Praluent | alirocumab |
0024-5904 | Praluent | alirocumab |
61755-020 | Praluent | alirocumab |
72733-5901 | Praluent | Praluent |
72733-5902 | Praluent | Praluent |
61755-021 | Praluent | Praluent |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
PRALUENT 86318389 4659691 Live/Registered |
SANOFI BIOTECHNOLOGY 2014-06-24 |